Navigation Links
Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
Date:11/7/2007

other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

INTERLEUKIN GENETICS, INC. AND SUBSIDIARIES

FINANCIAL HIGHLIGHTS

Balance Sheet Data:

September 30, December 31,

2007 2006

(Unaudited) (Audited)

Cash and cash equivalents $8,058,276 $10,082,919

Total current assets 10,468,352 12,991,113

Total assets $18,795,836 $22,630,285

Total current liabilities $6,927,948 $7,388,353

Total liabilities 9,157,742 8,844,354

Total shareholders' equity 9,638,094 13,785,931

Total liabilities and shareholders'

equity $18,795,836 $22,630,285

Statement of

Operations Data Three Months Ended Nine Months Ended

(Unaudited): September 30, September 30,

2007 2006 2007 2006

Revenue:

Genetic testing

service revenue $157,645 $654,482 $648,910 $2,219,145

Net consumer

products sales 1,792,688 674,725 5,173,555 674,725

Contract research

revenue 609,234 - 1,558,206 -

Other 1,718 5,724 8,360 17,975

Total revenue 2,561,285 1,334,931 7,389,031 2,911,845

Operating costs and

expenses:

Cost of genetic

testing services 211,953 331,836
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 1 SynCo Bio Partners B.V., the,expert in long ... has expanded its business into a new geographical,market, with ... biotherapeutic,for an emerging Japanese pharmaceutical company. , ... live biotherapeutic,based anticancer drug. The project will first involve ...
... , , FORT LAUDERDALE, Fla., ... a leader in integrated electronic data capture (EDC) ... fastest growing companies in the EDC marketplace, announced today that ... have joined its rapidly expanding partnership program, the CRO Preferred ...
... , , SOUTH SAN FRANCISCO, ... changing the paradigm of drug discovery and development through the ... Plunkett, Ph.D., as vice president and chief financial officer. , ... term success, and Matt,s career over the last decade has given ...
Cached Biology Technology:SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer 2
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Conservation Society in an atoll reef lagoon in Glover,s ... encouraging increases in populations of predatory fish species. However, ... herbivorous fish, which feed on the algae that smother ... will help WCS researchers in their search for new ...
... Va. Battlefield corpsmen and medical professionals across the country ... and Drug Administration approved the first hand-held device to ... the unit, called the Infrascanner, was initiated and funded ... portable, battery-powered medical device reveals intracranial hematomas soon after ...
... -- Bioengineers at Tufts University School of Engineering ... deliver precise amounts of drugs over time and without ... under normal temperature and pressure and from water, so ... maintain their activity prior to use. They are also ...
Cached Biology News:Belize protected area boosting predatory fish populations 2Belize protected area boosting predatory fish populations 3Naval technology could be a lifesaver 2Silk microneedles deliver controlled-release drugs painlessly 2
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Biology Products: